Abstract 1067: MatchMiner: An open-source AI precision medicine trial matching platform
Authors: Klein Harry , Mazor Tali , Galvin Matthew , Hansel Jason , Mallaber Emily , Trukhanov Pavel , Yu Joyce , Lindsay James , Kehl Kenneth , Hassett Michael , Cerami Ethan 
Published: June 2023

Abstract
As the number of precision medicine (PM) trials and patient genomic data has grown, it has become challenging for clinicians and trial staff to identify PM trial options for patients. Several trial matching software platforms have been developed to match genomic data from patients with PM trials, but these existing platforms are proprietary and are not easily accessible for adoption by institutions. At Dana-Farber Cancer Institute (DFCI), we have addressed this challenge by developing our own open-source institutional trial matching software, MatchMiner. MatchMiner algorithmically matches patient genomic and clinical data with PM trial eligibility data. Trial eligibility data is manually curated into a human-readable markup language, called clinical trial markup language (CTML), for matching with patient genomic data. MatchMiner has 2 main modes of clinical use: (1) patient-centric, where clinicians search for trial matches for individual patients and (2) trial-centric, where trial staff identify patients that match their trial’s genomic eligibility.
We recently described MatchMiner’s usage at DFCI and since our report, we have added 90 additional trial consents facilitated by MatchMiner (&gt;250 trial consents, called MatchMiner consents [MMC]). Here, we describe new characteristics of our MMC including which user mode (patient-centric or trial-centric) was used to match the consent, genomic alterations and cancer types that matched to eligibility criteria, and whether the patient went onto trial. MMCs were mostly identified by patient-centric mode (70%), genomic alterations and cancer types among MMC were diverse (n=55 genes and n=20 cancer types), and 87% of MMC went on trial. Among MMCs, the most common altered genes leading to trial eligibility were ERBB2 and KRAS in breast cancer and lung cancer, which is consistent with the number of therapies targeting ERBB2 and KRAS. MMCs also included patients with rare cancer types, like extraskeletal myxoid chondrosarcoma, as well as rare genomic alterations, such as NTRK fusions. Thus, MatchMiner has been successful at facilitating PM trial matching for a broad range of genomic alterations and cancer types at DFCI.
MatchMiner matches patients to trials as soon as their genomic report is available, however, many patients are not yet ready to enroll onto a trial because their cancer is responding to the standard of care or they are in a remission period. To address this problem, we are evaluating the use of artificial intelligence (AI) to identify patients that may be ready for a new treatment option. After trial matches have been generated by MatchMiner, radiology scan text from patients’ tumor scans is run through a natural language processing (NLP) model to identify patients who are more likely to be ready to enroll onto a trial. By using NLP to filter trial matches, we hope to improve MatchMiner’s efficiency of finding trial matches and provide more timely trial options for patients.
Citation Format: Harry Klein, Tali Mazor, Matthew Galvin, Jason Hansel, Emily Mallaber, Pavel Trukhanov, Joyce Yu, James Lindsay, Kenneth Kehl, Michael Hassett, Ethan Cerami. MatchMiner: An open-source AI precision medicine trial matching platform [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1067.